Medical product safety surveillance: How many databases to use?

Epidemiology

Volumn 24, Issue 5, 2013, Pages 692-699

  Maro, Judith C ^a   Brown, Jeffrey S ^b   Kulldorff, Martin ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; DATA BASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEASUREMENT ERROR; MEDICAL DEVICE REGULATION; MEDICAL PRODUCT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODUCT SAFETY; PUBLIC HEALTH; RISK ASSESSMENT; VACCINATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; HUMANS; MODELS, STATISTICAL; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES;

EID: 84881551256     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31829dde59     Document Type: Article

References (42)

1. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: A model for monitoring immunization safety. Pediatrics. 2011;127(suppl 1):S45-S53
2. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: Status and direction. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):1-8
3. Nguyen M, Ball R, Midthun K, Lieu TA . The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: Strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):291-297
4. Yih WK, Lee GM, Lieu TA, et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol. 2012;175:1120-1128. Available at: Http://aje.oxfordjournals. org/content/early/2012/05/10/aje. kws197. Accessed 24 May 2012
5. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: The experience of the Vaccine Safety Datalink project. Pediatrics. 2011;127(suppl 1):S54-S64
6. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Chichester, UK: Wiley; 1997
7. Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2000
8. Nelson JC, Cook AJ, Yu O, et al. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):62-71
9. Kulldorff M. Sequential statistical methods for prospective postmarketing safety surveillance. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. 5th ed. John Wiley & Sons; 2011:852-867
10. Maro JC, Brown JS. Impact of exposure accrual on sequential postmarket evaluations: A simulation study. Pharmacoepidemiol Drug Saf. 2011;20:1184-1191
11. Coloma PM, Trifirò G, Schuemie MJ, et al.; EU-ADR Consortium. Electronic healthcare databases for active drug safety surveillance: Is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21:611-621
12. Fireman B, Toh S, Butler MG, et al. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):282-290
13. Kittelson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics. 1999;55:874-882
14. Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med. 2007;26:5047-5080
15. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663
16. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu TA, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal. 2011;30:58-78
17. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012;30:2024-2031
18. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279-8284
19. Lee GM, Greene SK, Weintraub ES, et al.; Vaccine Safety Datalink Project. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011;41:121-128
20. Greene SK, Kulldorff M, Yin R, et al. Near real-Time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol Drug Saf. 2011;20:583-590
21. Belongia EA, Irving SA, Shui IM, et al.; Vaccine Safety Datalink Investigation Group. Real-Time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-Derived rotavirus vaccine. Pediatr Infect Dis J. 2010;29:1-5
22. Greene SK, Kulldorff M, Lewis EM, et al. Near real-Time surveillance for influenza vaccine safety: Proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol. 2010;171:177-188
23. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-Diphtheria-Acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009;27:4257-4262
24. Lieu TA, Kulldorff M, Davis RL, et al.; Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-Time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 suppl 2):S89-S95
25. Brown JS, Kulldorff M, Petronis KR, et al. Early adverse drug event signal detection within population-based health networks using sequential methods: Key methodologic considerations. Pharmacoepidemiol Drug Saf. 2009;18:226-234
26. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):23-31
27. Mullooly JP. Misclassification model for person-Time analysis of automated medical care databases. Am J Epidemiol. 1996;144:782-792
28. Brenner H, Gefeller O. Use of the positive predictive value to correct for disease misclassification in epidemiologic studies. Am J Epidemiol. 1993;138:1007-1015
29. Green MS. Use of predictive value to adjust relative risk estimates biased by misclassification of outcome status. Am J Epidemiol. 1983;117:98-105
30. Yoon K, Hwang CL. Multiple Attribute Decision Making : An Introduction. Thousand Oaks, CA: Sage Publications; 1995
31. Keeney RL. Decision analysis: An overview. Oper Res. 1982;30:803-838
32. Cook AJ, Tiwari RC, Wellman RD, et al. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: Current state of the art for use in the Mini-Sentinel pilot. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):72-81
33. Nelson JC, Cook AJ, Yu O, Zhao S, Jackson LA, Psaty BM. Methods for observational post-Licensure medical product safety surveillance. Stat Methods Med Res. 2011. Available at: Http://www.ncbi.nlm.nih.gov/ pubmed/22138688. Accessed 1 August 2012
34. Li L. A conditional sequential sampling procedure for drug safety surveillance. Stat Med. 2009;28:3124-3138
35. Zhao S, Cook A, Jackson L, Nelson J. Statistical performance of group sequential methods for observational post-Licensure medical product safety surveillance: A simulation study. Stat Its Interf. 2012;5: 381-390
36. Ray WA. Improving automated database studies. Epidemiology. 2011;22:302-304
37. Manuel DG, Rosella LC, Stukel TA . Importance of accurately identifying disease in studies using electronic health records. BMJ. 2010; 341:c4226
38. van Walraven C, Bennett C, Forster AJ. Administrative database research infrequently used validated diagnostic or procedural codes. J Clin Epidemiol. 2011;64:1054-1059
39. Strom BL. Methodologic challenges to studying patient safety and comparative effectiveness. Med Care. 2007;45(10 suppl 2):S13-S15
40. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337
41. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: Selecting alerting rules. Epidemiology. 2012;23:238-246
42. Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An eventbased approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012;21:631-639